| |
Total sample
|
CN
|
MCI
|
AD
|
p value
|
|---|
|
N (%)
|
50
|
36 (72)
|
8 (16)
|
6 (12)
| |
|
PET-Aβ+ (%)
|
23 (46)
|
12 (35)
|
5 (71)
|
6 (100)
|
0.0029
|
|
Gender male, N (%)
|
21 (42)
|
14 (39)
|
3 (38)
|
4 (67)
|
0.54
|
|
Mean age, years (SD)
|
72.8 (5.8)
|
73.1 (5.6)
|
73.5 (7.3)
|
70.5 (5.3)
|
0.42
|
|
APOE ε4 carriage, N (%)
|
16 (32)
|
9 (25)
|
4 (50)
|
4 (50)
|
0.26
|
|
Median MMSE, (MAD)
|
28 (3)
|
29 (1.5)
|
27 (2.2)
|
23.5 (4.4)
|
0.0019
|
|
Median CDR score, (MAD)
|
0 (0)
|
0 (0)
|
0.5 (0)
|
1 (0.4)
|
< 0.0001
|
- Abbreviations: N number, CN cognitively normal, MCI mild cognitive impairment, AD Alzheimer’s disease, APOE ε4 Apolipoprotein E epsilon 4 allele, APOE ε4 Carriage, N (%) number of participants with at least one APOE ε4 allele, MMSE Mini-Mental State Examination, CDR Clinical Dementia Rating, IQR inter-quartile range, MAD maximum absolute deviation, PET-Aβ Positron Emission Tomography Amyloid Beta. p value determined by t-test (age), chi-square analyses (PET-Aβ status, APOE ε4, and gender) and Kruskal-Wallis tests (CDR score and MMSE)
